Document is current
Any future updates will be listed below
-
Authors
Katayama, Naoki
Ohuchida, Kenoki
Son, Kiwa
Tsutsumi, Chikanori
Mochida, Yuki
Noguchi, Shoko
Iwamoto, Chika
Torata, Nobuhiro
Horioka, Kohei
Shindo, Koji
Mizuuchi, Yusuke
Ikenaga, Naoki
Nakata, Kohei
Oda, Yoshinao
Nakamura, Masafumi
-
Funding
Funding for this research was provided by:
Kaken Pharmaceutical (JP22H00480, JP23K27461, JP22K07171, JP23K08175, JP24K11743, JP24K11849)
- License Information
-
More Information
Article History
Received: 13 August 2024
Accepted: 16 December 2024
First Online: 25 December 2024
Declarations
:
: For sample collection for scRNA-seq, written consent was obtained from all patients who participated in this study. After approval by the Ethics Committee of Kyushu University (approval number: #2023–79), we complied with the “Ethical Guidelines for Life Sciences and Medical Research Involving Human Subjects” and the principles of the Declaration of Helsinki. The immunohistochemistry and immunofluorescence samples were used according to a protocol approved by the Kyushu University Clinical Trials Accreditation Committee (#22002–01).
